U.S FDA sanctions Boston Scientific Corporation’s Spectra WaveWriter SCS System
Boston Scientific Corporation asserted the successful approval of its Spectra Wavewriter Spinal Cord System by U.S FDA to met out paresthesia – based and sub- perception therapy permitting the system to combine therapeutic options and obtain real- time feedback designed to mitigate chronic pain thus alleviating pain eventually.
SCS designed to send low electric pulses varying in frequency, pulse width and amplitude to the spinal cord disrupting pain signals. Paresthesia-based therapy provides pain relief with a light tingling sensation while sub-perception therapy works without that sensation offering targeted pain relief by combining these systems.
Dr. Giancarlo Barolat, neurosurgeon, Barolat Neuroscience, Denver, Colorado said “Until now, the medical community has had limited options to offer personalized pain relief therapy to patients. The main advantage of the Spectra WaveWriter System is that it integrates multiple therapies into a single device so that treatment can more easily be tailored to individual needs.”
SCS claims to be a non- opioid alternative having been developed almost a decade ago as a result of extensive research. As more than 100 million Americans is allegedly grappling with chronic pain testifying major disability in the U.S..